Parenteral Drugs (India) Ltd
Incorporated in 1983, Parenteral Drugs Ltd
is engaged in Manufacturing and Trading of Pharmaceutical Products
- Market Cap ₹ 8.65 Cr.
- Current Price ₹ 2.90
- High / Low ₹ 4.14 / 2.70
- Stock P/E
- Book Value ₹ -276
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -48.3% over past five years.
- Contingent liabilities of Rs.135 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
482 | 333 | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 8 | |
433 | 319 | 341 | 349 | 248 | 296 | 249 | 225 | 50 | 47 | 24 | 24 | |
Operating Profit | 50 | 14 | -14 | -75 | 14 | -36 | -19 | -1 | -18 | -15 | -12 | -15 |
OPM % | 10% | 4% | -4% | -27% | 5% | -14% | -8% | -1% | -55% | -46% | -97% | -177% |
1 | 0 | 0 | 107 | 1 | 2 | 3 | 2 | 1 | 0 | 0 | 52 | |
Interest | 29 | 48 | 56 | 60 | 70 | 70 | 86 | 98 | 96 | 110 | 125 | 106 |
Depreciation | 13 | 14 | 23 | 19 | 31 | 23 | 25 | 24 | 69 | 17 | 17 | 40 |
Profit before tax | 9 | -49 | -93 | -47 | -86 | -127 | -127 | -121 | -181 | -142 | -154 | -109 |
Tax % | 46% | -10% | -16% | 3% | 22% | 8% | 8% | 8% | 18% | 20% | 21% | 30% |
5 | -53 | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
EPS in Rs | 1.71 | -20.64 | -41.69 | -15.15 | -22.69 | -39.09 | -39.52 | -37.50 | -49.61 | -38.26 | -40.82 | -25.61 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -31% |
5 Years: | -48% |
3 Years: | -36% |
TTM: | -30% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | 4% |
TTM: | -6% |
Stock Price CAGR | |
---|---|
10 Years: | -21% |
5 Years: | -16% |
3 Years: | -8% |
1 Year: | -15% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 26 | 26 | 26 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
Reserves | 300 | 311 | 203 | 157 | 82 | 278 | -47 | -166 | -477 | -591 | -713 | -854 |
Preference Capital | 6 | 12 | 17 | 15 | 15 | 18 | 0 | 125 | 77 | 77 | 77 | |
326 | 383 | 484 | 524 | 565 | 652 | 772 | 642 | 562 | 559 | 559 | 107 | |
104 | 129 | 123 | 114 | 108 | 106 | 159 | 385 | 426 | 554 | 692 | 1,201 | |
Total Liabilities | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
406 | 500 | 610 | 571 | 542 | 892 | 739 | 716 | 356 | 339 | 322 | 205 | |
CWIP | 79 | 116 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 2 |
267 | 233 | 221 | 253 | 242 | 174 | 175 | 175 | 182 | 210 | 244 | 276 | |
Total Assets | 755 | 850 | 835 | 825 | 785 | 1,066 | 914 | 890 | 541 | 552 | 568 | 484 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
78 | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | -0 | |
-113 | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | 65 | |
31 | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | -64 | |
Net Cash Flow | -5 | 5 | -3 | -2 | -5 | 1 | -0 | -0 | 0 | 0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 81 | 101 | 88 | 161 | 194 | 130 | 99 | 6 | 0 | 0 | 0 | 0 |
Inventory Days | 118 | 149 | 121 | 128 | 232 | 112 | 107 | 68 | 224 | 73 | 103 | 69 |
Days Payable | 79 | 157 | 112 | 99 | 177 | 77 | 101 | 130 | 671 | 458 | 504 | 654 |
Cash Conversion Cycle | 120 | 93 | 97 | 189 | 249 | 164 | 105 | -55 | -446 | -385 | -401 | -585 |
Working Capital Days | 106 | 103 | 115 | 133 | 144 | 15 | -248 | -560 | -9,244 | -10,747 | -32,260 | -48,682 |
ROCE % | 6% | -0% | -5% | -4% | -2% | -7% | -5% | -3% | -21% | -24% | -213% |
Documents
Announcements
-
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
10h - The Tenth meeting of Committee of Creditors (CoC), pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 (LODR) and in accordance with the requirements of …
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
10h - In accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we would like to inform …
- Request For Deletion Of Recently Submitted The Inadvertent Corporate Announcement Regarding Approval Of Resolution Plan In The 9Th Meeting Of Committee Of Creditors ('Coc') Of Parenteral Drugs (India) Limited, The Corporate Debtor 2 Apr
-
Approval Of Resolution Plan By COC
2 Apr - In accordance with the requirements of sub- clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations, we wish to inform …
- Closure of Trading Window 30 Mar
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1]
a) IV Fluids:[2] Carbohydrate and Electrolytes, Diuretics, Dialysis & Irrigation Solution, Anti-infective & Anti-fungal
b) Oncology:[3] Injections, Tablets and Capsules
c) Anaesthesia:[4] Sevoplan, Isoplan